573 related articles for article (PubMed ID: 15134571)
1. PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS.
Elsinga PH; Hendrikse NH; Bart J; Vaalburg W; van Waarde A
Curr Pharm Des; 2004; 10(13):1493-503. PubMed ID: 15134571
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography studies on binding of central nervous system drugs and P-glycoprotein function in the rodent brain.
Elsinga PH; Hendrikse NH; Bart J; van Waarde A; Vaalburg W
Mol Imaging Biol; 2005; 7(1):37-44. PubMed ID: 15912274
[TBL] [Abstract][Full Text] [Related]
3. Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.
Wanek T; Römermann K; Mairinger S; Stanek J; Sauberer M; Filip T; Traxl A; Kuntner C; Pahnke J; Bauer F; Erker T; Löscher W; Müller M; Langer O
Mol Pharm; 2015 Sep; 12(9):3214-25. PubMed ID: 26202880
[TBL] [Abstract][Full Text] [Related]
4. (18)F-FCWAY, a serotonin 1A receptor radioligand, is a substrate for efflux transport at the human blood-brain barrier.
Liow JS; Zoghbi SS; Hu S; Hall MD; Hines CS; Shetty HU; Araneta MD; Page EM; Pike VW; Kreisl WC; Herscovitch P; Gottesman MM; Theodore WH; Innis RB
Neuroimage; 2016 Sep; 138():134-140. PubMed ID: 27211474
[TBL] [Abstract][Full Text] [Related]
5. (R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation.
Luurtsema G; Molthoff CF; Windhorst AD; Smit JW; Keizer H; Boellaard R; Lammertsma AA; Franssen EJ
Nucl Med Biol; 2003 Oct; 30(7):747-51. PubMed ID: 14499333
[TBL] [Abstract][Full Text] [Related]
6. Functional Expression of P-glycoprotein and Organic Anion Transporting Polypeptides at the Blood-Brain Barrier: Understanding Transport Mechanisms for Improved CNS Drug Delivery?
Abdullahi W; Davis TP; Ronaldson PT
AAPS J; 2017 Jul; 19(4):931-939. PubMed ID: 28447295
[TBL] [Abstract][Full Text] [Related]
7. Abundance of P-Glycoprotein and Other Drug Transporters at the Human Blood-Brain Barrier in Alzheimer's Disease: A Quantitative Targeted Proteomic Study.
Storelli F; Billington S; Kumar AR; Unadkat JD
Clin Pharmacol Ther; 2021 Mar; 109(3):667-675. PubMed ID: 32885413
[TBL] [Abstract][Full Text] [Related]
8. Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates.
Damont A; Goutal S; Auvity S; Valette H; Kuhnast B; Saba W; Tournier N
Eur J Pharm Sci; 2016 Aug; 91():98-104. PubMed ID: 27283486
[TBL] [Abstract][Full Text] [Related]
9. Advances in PET imaging of P-glycoprotein function at the blood-brain barrier.
Syvänen S; Eriksson J
ACS Chem Neurosci; 2013 Feb; 4(2):225-37. PubMed ID: 23421673
[TBL] [Abstract][Full Text] [Related]
10. [PET imaging to study the functional impact of P-glycoprotein in neuropharmacokinetics].
Marie S; Tournier N
Therapie; 2020; 75(6):623-632. PubMed ID: 32200996
[TBL] [Abstract][Full Text] [Related]
11. Radioligands targeting P-glycoprotein and other drug efflux proteins at the blood-brain barrier.
Wanek T; Mairinger S; Langer O
J Labelled Comp Radiopharm; 2013; 56(3-4):68-77. PubMed ID: 24285312
[TBL] [Abstract][Full Text] [Related]
12. Selective induction of P-glycoprotein at the CNS barriers during symptomatic stage of an ALS animal model.
Chan GN; Evans RA; Banks DB; Mesev EV; Miller DS; Cannon RE
Neurosci Lett; 2017 Feb; 639():103-113. PubMed ID: 28011392
[TBL] [Abstract][Full Text] [Related]
13. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases.
Löscher W; Potschka H
Prog Neurobiol; 2005 May; 76(1):22-76. PubMed ID: 16011870
[TBL] [Abstract][Full Text] [Related]
14. Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening.
Tournier N; Valette H; Peyronneau MA; Saba W; Goutal S; Kuhnast B; Dollé F; Scherrmann JM; Cisternino S; Bottlaender M
J Nucl Med; 2011 Mar; 52(3):415-23. PubMed ID: 21321274
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Preclinical Evaluation of Three Novel Fluorine-18 Labeled Radiopharmaceuticals for P-Glycoprotein PET Imaging at the Blood-Brain Barrier.
Savolainen H; Cantore M; Colabufo NA; Elsinga PH; Windhorst AD; Luurtsema G
Mol Pharm; 2015 Jul; 12(7):2265-75. PubMed ID: 26043236
[TBL] [Abstract][Full Text] [Related]
16. Enhanced cerebral uptake of receptor ligands by modulation of P-glycoprotein function in the blood-brain barrier.
Doze P; Van Waarde A; Elsinga PH; Hendrikse NH; Vaalburg W
Synapse; 2000 Apr; 36(1):66-74. PubMed ID: 10700027
[TBL] [Abstract][Full Text] [Related]
17. Combining PET biodistribution and equilibrium dialysis assays to assess the free brain concentration and BBB transport of CNS drugs.
Gunn RN; Summerfield SG; Salinas CA; Read KD; Guo Q; Searle GE; Parker CA; Jeffrey P; Laruelle M
J Cereb Blood Flow Metab; 2012 May; 32(5):874-83. PubMed ID: 22274741
[TBL] [Abstract][Full Text] [Related]
18. Importance of P-gp PET Imaging in Pharmacology.
Toyohara J
Curr Pharm Des; 2016; 22(38):5830-5836. PubMed ID: 27494065
[TBL] [Abstract][Full Text] [Related]
19. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.
Kuntner C; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Stundner G; Karch R; Brauner R; Meier M; Ding X; Müller M; Löscher W; Langer O
Eur J Nucl Med Mol Imaging; 2010 May; 37(5):942-53. PubMed ID: 20016890
[TBL] [Abstract][Full Text] [Related]
20. Monitoring interactions at ATP-dependent drug efflux pumps.
Hendrikse NH
Curr Pharm Des; 2000 Nov; 6(16):1653-68. PubMed ID: 10974159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
